Depemokimab in eosinophilic asthma – a new era in biological therapy?

Article Sidebar

PDF
Published: Mar 28, 2025
DOI: https://doi.org/10.7196/

Main Article Content

S Pillay
Pulmonology Fellow, Division of Pulmonology, Department of Medicine, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa

Abstract

-

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Pillay S. Depemokimab in eosinophilic asthma – a new era in biological therapy?. Afr J Thoracic Crit Care Med [Internet]. 2025 Mar. 28 [cited 2025 Apr. 22];31(1):e3332. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/3332
Issue
AJTCCM Vol. 31 No. 1
Section
Breath-Taking News
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited. 

Exceptions to this license model is allowed for UKRI and research funded by organisations requiring that research be published open-access without embargo, under a CC-BY licence. As per the journals archiving policy, authors are permitted to self-archive the author-accepted manuscript (AAM) in a repository. 

How to Cite

1.
Pillay S. Depemokimab in eosinophilic asthma – a new era in biological therapy?. Afr J Thoracic Crit Care Med [Internet]. 2025 Mar. 28 [cited 2025 Apr. 22];31(1):e3332. Available from: https://samajournals.co.za/index.php/ajtccm/article/view/3332

References

1. Jackson DJ, Wechsler ME, Jackson DJ, et al. Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype. N Engl J Med 2024;391(24):2337-2349. https://doi.org/10.1056/NEJMoa2406673

2. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): A multicentre, double-blind, placebo-controlled trial. Lancet 2012;380(9842):651-659. https://doi.org/10.1016/S0140-6736(12)60988-X

3. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353(5):487- 497. https://doi.org/10.1056/NEJMra050100

4. Crimi C, Calabrese C, D’Amato M, et al. Patient and physician perspectives on biological treatment in severe asthma: A Severe Asthma Network Italy survey. ERJ Open Res 2023;9(6):00560-2023. https://doi.org/10.1183/23120541.00560-2023

5. Lion-Cachet HC, Musonda JMM, Omole OB. Severe asthma in South Africa: A literature review and management approach for primary care. S Afr Fam Pract 2021;63(1):e1-e10. https://doi.org/10.4102/safp. v63i1.5179

6. GlobalInitiativeforAsthma.GlobalStrategyforAsthmaManagementandPrevention, 2024. www.ginasthma.org (accessed 19 February 2025).